阿替唑单抗
CD8型
医学
细胞
癌症研究
肺癌
PD-L1
化疗
T细胞
转录组
免疫疗法
封锁
肿瘤科
癌症
生物
内科学
免疫学
基因
受体
免疫系统
基因表达
无容量
生物化学
遗传学
作者
Namrata S. Patil,Barzin Y. Nabet,Sören Müller,Hartmut Koeppen,Wei Zou,Jennifer M. Giltnane,Amelia Au-Yeung,Shyam Srivats,Jason H. Cheng,Chikara Takahashi,Patrícia E. de Almeida,Avantika S. Chitre,Jane L. Grogan,Linda Rangell,Sangeeta Jayakar,Maureen Peterson,Allison W. Hsia,William O’Gorman,Marcus Ballinger,Romain Banchereau,David S. Shames
出处
期刊:Cancer Cell
[Elsevier]
日期:2022-03-01
卷期号:40 (3): 289-300.e4
被引量:154
标识
DOI:10.1016/j.ccell.2022.02.002
摘要
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) benefit. Using transcriptomic analysis of 891 NSCLC tumors from patients treated with either the PD-L1 inhibitor atezolizumab or chemotherapy from two large randomized clinical trials, we find a significant B cell association with extended OS with PD-L1 blockade, independent of CD8+ T cell signals. We then derive gene signatures corresponding to the dominant B cell subsets present in NSCLC from single-cell RNA sequencing (RNA-seq) data. Importantly, we find increased plasma cell signatures to be predictive of OS in patients treated with atezolizumab, but not chemotherapy. B and plasma cells are also associated with the presence of tertiary lymphoid structures and organized lymphoid aggregates. Our results suggest an important contribution of B and plasma cells to the efficacy of PD-L1 blockade in NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI